9 results about "Sleep wake" patented technology

The present invention addresses the problem of providing a novel compound that has an OX2R agonist activity.　The present invention relates to a substituted sulfonamide compound which is represented by formula (I) or a pharmacologically acceptable salt thereof. A compound according to the present invention, or a pharmacologically acceptable salt thereof, has an agonist activity against OX2R, and is useful as, for example, a therapeutic agent for sleep disorders associated with OX2R (for example, narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorders, insufficient sleep syndrome, and extended sleep).

The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

The present invention addresses the problem of providing a novel compound that has OX2R agonist activity.　The present invention relates to a substituted sulfonamide macrocyclic compound represented by formula (I) or a pharmacologically acceptable salt thereof. This compound, or a pharmacologically acceptable salt thereof, has agonist activity against OX2R, and is useful as a treatment agent, etc., for sleep disorders involving OX2R (e.g., narcolepsy, idiopathic hypersomnia, Kleine-Levin syndrome, hypersomnia associated with a physical disease, hypersomnia associated with a mental disease, hypersomnia associated with a drug or a substance, circadian rhythm sleep-wake disorder, insufficient sleep syndrome, and extended sleep).

The invention relates to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder, in particular to an application of propylamine bromide (C23H30BrNO3) in the treatment of sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, so that long-term use of the traditional sleep drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely propylamine bromide, in preparation of drugs for treating sleep disorders is provided for the first time, especially those which are insensitive to existing sedative drugs or related to circadian rhythm disorder, and have no toxic or side effects on sleep disorders. The optimal curative effect can be achieved in the indications by 20 mu M, the sleep-awakening cycle disorder caused by PER3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention relates to an application of atropine (Atropine, C17H23NO3) in preparation of a medicine for treating sleep disorder. Existing sleep drugs are generally ineffective to sleep disorders related to circadian rhythm and cannot restore a normal sleep-awakening period for many patients, and benzodiazepine and non-benzodiazepine hypnotics have significant side effects such as dependency, cognitive disorder and dizziness, and long-term use of the drugs is limited. According to the invention, a per3 gene defect zebrafish model is used for drug screening, and a new application of a clinically used drug, namely atropine, in preparation of drugs for treating sleep disorders is provided for the first time, especially for treating sleep disorders which are insensitive to existing sedative drugs or are related to circadian rhythm disorder, and particularly for treating sleep disorders which are not sensitive to existing sedative drugs or are related to circadian rhythm disorder, circadian rhythm disorder, circadian rhythm disorder and circadian rhythm disorder. The optimal curative effect can be achieved in the indication by 12 mu M, the sleep-awakening cycle disorder caused by Per3 defects is improved, and the normal sleep-awakening cycle is recovered.

The invention relates to an anti-depression compound 4-methyl-6-methoxy coumarin, and belongs to the technical field of biological medicines. Depression is the most common mental disorder in the world and is also a main reason for disability. The development of a novel anti-depression drug which is based on a nerve plasticity mechanism, takes effect quickly, has a lasting curative effect and is high in safety, and particularly has important clinical requirements and technical necessity for an effective treatment means for refractory depression. Traditional Chinese medicine monomers and a per2- / -zebra fish depression model are adopted for anti-depression drug screening, and finally it is found that 10 mM of 4-methyl-6-methoxycoumarin has the anti-depression characteristic and has the positive treatment effect on the exploration behavior, social interaction and sleep-awakening period of per2- / -zebra fish. The method can effectively rescue and reverse depression-like phenotypes observed in a per2- / -zebra fish circadian rhythmic depression model, and can restore the balance of important gene expression.

The invention provides methods of improving sleep in a patient having a variant of the cryptochrome circadian clock 1 (CRY1) genotype associated with a circadian rhythm sleep disorder (CRSD) Delayed Sleep Wake Phase Disorder (DSWPD).

Disclosed are novel compositions, devices, patches, systems and methods that are useful for estimating, determining, modulating and / or improving the sleep / wake and / or circadian phase of a subject (e.g., a human subject) by the dispensing of measured quantities of agents to a subject or into an environment of the subject and the continuous monitoring and / or tracking of the subject's consciousness (e.g., sleep / wake) patterns. In certain aspects, the compositions, devices, patches, systems and methods disclosed herein are capable of delivering one or more agents to a subject in response to measured consciousness patterns estimations and circadian phase estimations, thereby aligning the subject's circadian biology to the external environment and improving the quality and duration of sleep.

A method for detecting a circadian rhythm of a user, which includes acquiring measurement data indicating the user's sleep time and determining a user's sleep-wake rhythm of the user based on the measurement data; determining a first phase value based on the sleep-wake rhythm; acquiring skin temperature measurement data for at least one 24-hour measurement period, fitting the skin temperature measurement data to a cosine waveform, and performing evaluation of a quality of the fitting and, if the quality is above a threshold, determining a second phase value on the basis of the fitting; if the quality of the fitting is above the threshold, determining a circadian phase of the user on the basis of a combination of the first phase value and the second phase value; if the quality of the fitting is below the threshold, determining a circadian phase of the user based on the first phase value without the second phase value; and outputting the computed circadian phase or a parameter derivative of the computed circadian phase via an interface to the user.